Research location

Freudenberg

Germany

Published trials7
Site observations7
Linked trials published7
Page1 / 1
Advertisement

Research activity in Freudenberg

Germany

CureCurrent currently publishes aggregate city-level research activity for this location: 7 trials and 7 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Freudenberg

7 linked trials · page 1 of 1
Study to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD RegimenNCT01985334 · 2014-02-14 · 1 site observation
COMPLETED
QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study, FLAME (EFfect of Indacaterol Glycopyronium Vs Fluticasone Salmeterol on COPD Exacerbations)NCT01782326 · 2013-07-01 · 1 site observation
COMPLETED
QVA149 Versus Fluticasone/Salmeterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)NCT01315249 · 2011-03-01 · 1 site observation
COMPLETED
Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) ExacerbationsNCT01120691 · 2010-04-01 · 1 site observation
COMPLETED
A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)NCT00900731 · 2009-06-01 · 1 site observation
COMPLETED
Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Using Salmeterol as Active ControlNCT00567996 · 2007-11-01 · 1 site observation
COMPLETED
A Follow-up Programme for Patients Using Symbicort SMART in Normal Clinical PracticeNCT00505388 · 2007-07-01 · 1 site observation
COMPLETED

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.